STUDY SEARCH RESULTS

1 study found for your search request:  7684A-010

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Ris...
Condition: Melanoma
Minimum Age: 12 years, Maximum Age: N/A
Gender: All
Study ID: NCT05665595
Status: Active, not recruiting




Copyright © 2024 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  U.S. Corporate Site